Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths
The highly unusual move is a latest in a string of events that have hammered the company's stock for weeks and recently forced it to lay off 500 employees. The company's decision not to comply with the
FDA
also places future availability of its leading therapy, called Elevidys, in doubt.
The FDA said in a statement Friday night that officials met with Sarepta and requested it suspend all sales but 'the company refused to do so.' The agency has the authority to pull drugs from the market, but the cumbersome regulatory process can take months or even years. Instead, the agency usually makes an informal request and companies almost always comply.
'We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges,' FDA Commissioner Marty Makary said in a statement.
Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects males, though it has faced scrutiny since its clearance in 2023. The one-time treatment received accelerated approval against the recommendations of some FDA scientists who doubted its effectiveness.
The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, including those who can no longer walk. Previously, it was only available for younger patients who were still walking.
Sarepta said Friday that its scientific review showed 'no new or changed safety signals' for younger patients with Duchenne's who have earlier stages of the disease. The company said it plans to keep the drug available for those patients.
'We look forward to continued discussions and sharing of information with FDA,' the company said in a statement.
Sarepta halted shipments last month of the therapy for older boys with Duchenne's, which gradually destroys muscle and skeletal strength, resulting in early death. The move followed the deaths of two teenage boys taking the therapy.
The company also confirmed a third death Friday: a 51-year-old patient who was taking an experimental gene therapy in a trial for a different form of muscular dystrophy. Sarepta said it reported the death to the FDA on June 20. The FDA said Friday it placed that trial on hold.
Sarepta noted that the gene therapy involved in the incident uses 'a different dose and is manufactured using a different process,' than Elevidys.
All three patient deaths were linked to liver injury, a side effect noted in Sarepta's prescribing information.
Earlier this week Sarepta announced it would add a bold warning to drug and lay off a third of its employees. The company did not mention the third patient death in its news release or conference call announcing those changes, sparking pointed criticism from Wall Street analysts.
Company shares fell more than 35% Friday to close at $14.07.
Cambridge, Massachusetts-based Sarepta has received FDA approval for three other Duchenne's drugs since 2016, none of which have been confirmed to work. The company has long been criticized for failing to complete several studies needed to secure full FDA approval of its drugs.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
22 minutes ago
- The Hill
Man dies after being pulled into MRI machine while wearing metal chain
WESTBURY, N.Y. (AP) — A man who was pulled into an MRI machine in New York after he walked into the room wearing a large weight-training chain around his neck has died, according to police and his wife, who told a local television outlet that he waved goodbye before his body went limp. The man, 61, had entered an MRI room while a scan was underway Wednesday afternoon at Nassau Open MRI. The machine's strong magnetic force drew him in by the metallic chain around his neck, according to a release from the Nassau County Police Department. He died Thursday afternoon, but a police officer who answered the phone at the Nassau County police precinct where the MRI facility is located said the department had not yet been given permission to release the name Saturday. Adrienne Jones-McAllister told News 12 Long Island in a recorded interview that she was undergoing an MRI on her knee when she asked the technician to get her husband, Keith McAllister, to help her get off the table. She said she called out to him. She told News 12 that the technician summoned into the room her husband, who was wearing a 20-pound chain that he uses for weight training, an object they'd had a casual conversation about during a previous visit with comments like: 'Ooooooh, that's a big chain!' When he got close to her, she said, 'at that instant, the machine switched him around, pulled him in and he hit the MRI.' 'I said: 'Could you turn off the machine, call 911, do something, Turn this damn thing off!'' she recalled, as tears ran down her face. 'He went limp in my arms.' She said the technician helped her try to pull her husband off the machine but it was impossible. 'He waved goodbye to me and then his whole body went limp,' Jones-McAllister told the TV outlet. Jones-McAllister told News 12 that McAllister suffered heart attacks after he was freed from the MRI machine. A person who answered the phone at Nassau Open MRI on Long Island declined to comment Friday. The phone number went unanswered on Saturday. It wasn't the first New York death to result from an MRI machine. In 2001, 6-year-old Michael Colombini of Croton-on-Hudson was killed at the Westchester Medical Center when an oxygen tank flew into the chamber, drawn in by the MRI's 10-ton electromagnet. In 2010, records filed in Westchester County revealed that the family settled a lawsuit for $2.9 million. MRI machines 'employ a strong magnetic field' that 'exerts very powerful forces on objects of iron, some steels, and other magnetizable objects,' according to the National Institute of Biomedical Imaging and Bioengineering, which says the units are 'strong enough to fling a wheelchair across the room.'
The Hill
22 minutes ago
- The Hill
We can't win the fight to end HIV if we cut funding and access to medication
The fight to end HIV in our lifetimes just received a game-changing innovation. In June, the FDA approved Yeztugo (lenacapavir), a groundbreaking HIV prevention treatment that requires just two injections per year — and scored 99 percent effectiveness in trials. This monumental scientific breakthrough is poised to transform the lives of people who have found it hard to keep up with daily oral pre-exposure prophylaxis, providing an option that fits better into their everyday lives. But as exciting as this development is, it could be undermined by the Trump administration's proposal to cut nearly $1 billion from federal HIV prevention programs. Innovations like lenacapavir could be a key tool to ending the epidemic, but only if we have the resources and policy to deliver it directly to those who need them most. Although lenacapavir's efficacy is groundbreaking, access remains another story. With a price tag hovering around $28,000 a year, this medication risks being out of reach for the very communities who need it most. We're still waiting to see how programs managed by Gilead Sciences, which developed the treatments, and the broader insurance markets will step up. And it's not just the cost of the drug itself. It's the labs, the provider visits, the follow-ups — each one a potential roadblock for someone trying to stay safe. Federal leadership is essential to ensuring this new HIV prevention tool reaches the communities who need it most. This includes updating clinical guidelines, funding support services and supporting the infrastructure that makes access possible. Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving innovations at risk. The administration's attacks on HIV prevention, including its proposals to eliminate the Centers for Disease Control and Prevention's HIV budget and efforts to dismantle public health systems, threaten progress. The Republican budget reconciliation bill that President Trump signed over the July 4 weekend includes deep cuts to Medicaid — the largest payer for HIV care in the U.S. Without strong federal investment and coordination, expanding access to new tools and ending the HIV epidemic is at serious risk. Despite the real strides we have made in HIV prevention, those of us in the lesbian, gay, and transgender community — especially non-white Southerners in rural areas or navigating poverty — know that not every prevention strategy reaches us, works for us, or is built with us in mind. Our realities demand options that reflect the full truth of who we are and how we live. Lenacapavir offers real, powerful hope, but let's be clear: Science alone won't save us. What will make the difference is equitable and intentional policies that center our communities and a public health infrastructure that doesn't leave us behind. These numbers don't shift on their own. Yes, we have made progress over time. But the hard truth is that Black Americans still account for 43 percent of all new HIV diagnoses in the U.S., despite being just 13 percent of the population. The data is even more stark for Black transgender women: 44 percent are living with HIV, and their lifetime risk remains unacceptably high. And we cannot ignore the geography of this epidemic. The South accounts for 52 percent of all new HIV diagnoses in the U.S. That's not a coincidence — it is the result of systemic failures: limited access to healthcare, persistent stigma, lack of comprehensive sex education and the absence of strong non-discrimination protections. These barriers don't just prevent care — they trap people in cycles where prevention tools are out of reach. Among gay and bisexual Black men, the risk of contracting HIV is still 50 percent over a lifetime. Prevention tools like pre-exposure prophylaxis and lenacapavir hold promise, but they only matter if people can actually access them, without fear, shame or coercion. Ending this epidemic means creating environments where people are safe to make informed choices about their own health. The fight to end the HIV epidemic is not just about what happens in labs — it's about how we make these innovations real for our communities. Science is doing its part. Now is the time to urge Congress to reject any cuts to CDC HIV prevention efforts and to fully fund the HIV response. We have the tools to end this epidemic, but not if we dismantle the very systems our communities rely on to survive. The promise of lenacapavir, and the hope it represents, is too great to let fall through the cracks of policy neglect. The question is, will we make the choice to ensure that this breakthrough reaches all of us? Science has given us the tools. Now, we must ensure that everyone has the opportunity to use them.
Yahoo
5 hours ago
- Yahoo
12,000 pounds of organic blueberries recalled over Listeria risk — here's what to know
The frozen berries were shipped to a single customer in North Carolina, but the FDA has issued its highest-level health warning. A frozen fruit recall is drawing national attention, but it all comes down to one state. North Carolina is the only area affected by a new FDA blueberry recall, after a batch of frozen organic fruit tested positive for Listeria monocytogenes during finished product testing. The fruit came from Alma Pak International, a Georgia-based supplier, and was shipped on or before June 9, 2025, to a single commercial customer. The FDA has since elevated the recall to Class I — the agency's highest risk category for products that pose a serious health threat if consumed. What's the Recall? Here are the details of the recall so that you can check for affected product in foodservice settings or repackaged goods. Alma Pak Organic Blueberries (frozen) Shipped in 30-pound bulk boxes Lot numbers: 13325 G1060 and 13325 G1096 The recalled blueberries were shipped to a single commercial customer in North Carolina. The FDA has not issued a consumer-facing press release, and the buyer has not been named. These berries were not sold directly to consumers, but could potentially have been used in food service, commercial baking, or other large-batch applications. No other Alma Pak products or lots are included in this recall. Why This Recall Matters Listeria monocytogenes is one of the most dangerous foodborne pathogens, and frozen fruit, while often considered lower risk, has been the source of several high-profile recalls in recent years. Unlike many other bacteria, Listeria can survive freezing temperatures, meaning contaminated fruit remains hazardous even straight from the freezer. While most healthy individuals may experience only mild symptoms, Listeria infections can be life-threatening for pregnant people, newborns, older adults, and immunocompromised individuals. This recall is especially concerning because the blueberries were shipped in bulk, unlabeled boxes. While there's no confirmed evidence the product reached consumers, it's possible the fruit was used in prepared foods like baked goods, smoothies, or frozen blends sold regionally. The Class I designation is not limited to E. coli or meat contamination. It applies to any situation where the FDA sees a 'reasonable probability' that exposure could cause serious illness, including Listeria, undeclared allergens, and other high-risk threats. What to Do If you operate a foodservice business or grocery in North Carolina, check with your distributor to determine whether the affected lot codes were received. The FDA recommends discarding any impacted product and thoroughly sanitizing any prep surfaces, containers, or equipment that may have come into contact with the berries. If you're a consumer who recently bought bulk or repackaged organic frozen blueberries, especially from a small grocer, farmers market, or co-op, ask whether they source fruit from Alma Pak. If you're not sure, it's safest to throw it out. Even frozen fruit isn't immune from contamination. A Class I recall means the risk is real and worth taking seriously, even in just one state. Solve the daily Crossword
